Comparative Pharmacology
Head-to-head clinical analysis: SULTEN 10 versus TRIMETH SULFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULTEN 10 versus TRIMETH SULFA.
SULTEN-10 vs TRIMETH/SULFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selectively inhibits type 5 phosphodiesterase (PDE5), enhancing cyclic guanosine monophosphate (cGMP) accumulation, leading to smooth muscle relaxation and vasodilation in the corpus cavernosum.
Trimethoprim inhibits bacterial dihydrofolate reductase (DHFR), blocking conversion of dihydrofolate to tetrahydrofolate; sulfamethoxazole inhibits bacterial dihydropteroate synthase, blocking incorporation of para-aminobenzoic acid into folic acid. Sequential blockade of folate synthesis produces synergistic bactericidal effect.
1 to 2 tablets (10-20 mg) orally once daily, preferably in the morning.
1 double-strength tablet (160 mg trimethoprim / 800 mg sulfamethoxazole) orally every 12 hours for 14 days.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours; clinically, this supports once-daily dosing with steady state achieved in 3-5 days.
Trimethoprim: 8-11 hours; Sulfamethoxazole: 9-11 hours. Prolonged in renal impairment (up to 24-30 hours for both). Clinical context: Dosing interval is typically 12 hours in normal renal function; adjust in CrCl <15-30 mL/min.
Primarily renal excretion of unchanged drug (approx. 70-80%) with the remainder as inactive metabolites (10-15% fecal, 5-10% biliary).
Trimethoprim: 50-60% unchanged in urine; Sulfamethoxazole: 15-30% unchanged in urine, with acetylation and glucuronidation metabolites. Approximately 80-90% of dose recovered in urine within 72 hours; remainder via feces.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic